Interaksi Salsalat

Salsalat, golongan OAINS, memiliki 303 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 47 mayor, 216 moderat, 40 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (47)

  • ApiksabanantikoagulanMayor

    …risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (label Apiksaban, Peringatan kotak hitam)

  • Asam mefenamatOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • AspirinOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • Aspirin dan dipiridamolantiplateletMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • DabigatranantikoagulanMayor

    …the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (label Dabigatran, Peringatan kotak hitam)

  • DiflunisalOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • DiklofenakOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • EdoksabanantikoagulanMayor

    …the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (label Edoksaban, Peringatan kotak hitam)

  • Avoid SYMFI with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.3) ] . (label Efavirenz, lamivudin, dan tenofovir, Peringatan dan perhatian)

  • COMPLERA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.4) ]. (label Emtrisitabin, rilpivirin, dan tenofovir, Peringatan dan perhatian)

  • EnoksaparinantikoagulanMayor

    …the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity… (label Enoksaparin, Peringatan kotak hitam)

  • EtodolakOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • FenoprofenOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • Fisostigminpenghambat kolinesteraseMayor

    Contraindications: ANTICHOLIUM ® should not be used in the presence of hypersensitivity to physostigmine salicylate, bronchial asthma, ulcers associated with tissue destruction (gangrene), coronary heart disease, constipation (mechanical obstipation), mechanical ischuria (urinary retention), hereditary form of muscle atrophy (myotonic dystrophy), closed traumatic… (label Fisostigmin, Kontraindikasi)

  • FlurbiprofenOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • FondaparinuksantikoagulanMayor

    …risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity… (label Fondaparinuks, Peringatan kotak hitam)

  • Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • IbuprofenOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • IndometasinOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • KetoprofenOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • KetorolakOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • MeloksikamOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • MetotreksatimunosupresanMayor

    Unexpectedly severe and fatal gastrointestinal toxicity can occur with concomitant administration of XATMEP (primarily at high dosage) and nonsteroidal anti-inflammatory drugs (NSAIDs) [see Drug Interactions ( 7.1 )] . (label Metotreksat, Peringatan dan perhatian)

  • Misoprostolanalog prostaglandinMayor

    MISOPROSTOL SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). (label Misoprostol, Peringatan kotak hitam)

  • Montelukastantagonis reseptor leukotrienMayor

    Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR ( 5.4 ). (label Montelukast, Peringatan dan perhatian)

  • NabumetonOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • NaproksenOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • OksaprozinOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • PiroksikamOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • PralatreksatantimetabolitMayor

    Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. (label Pralatreksat, Interaksi obat)

  • PrasugrelantiplateletMayor

    Additional risk factors for bleeding include: body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding (e.g . , warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Warnings and Precautions (5.1) ] . (label Prasugrel, Peringatan kotak hitam)

  • In patients on probenecid the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (label Probenesid, Peringatan)

  • In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (label Probenesid dan kolkisin, Peringatan)

  • RivaroksabanantikoagulanMayor

    …risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (label Rivaroksaban, Peringatan kotak hitam)

  • SelekoksibOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • SidofovirantivirusMayor

    Nephrotoxic agents Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and nonsteroidal anti-inflammatory agents] is contraindicated. (label Sidofovir, Interaksi obat)

  • SulindakOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

  • TenofovirantiretroviralMayor

    VIREAD should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.1) ] . (label Tenofovir, Peringatan dan perhatian)

  • TolmetinOAINSMayor

    Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (label Salsalat, Kontraindikasi)

Interaksi moderat (216)

  • AdapalenretinoidModerat

    Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with Adapalene Cream, 0.1%. (label Adapalen, Interaksi obat)

  • AdefovirantivirusModerat

    However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (label Adefovir, Peringatan dan perhatian)

  • AfatinibModerat

    Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (label Afatinib, Peringatan dan perhatian)

  • AkarbosaantidiabetesModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • AlendronatbisfosfonatModerat

    Use caution when co-prescribing aspirin/nonsteroidal anti- inflammatory drugs that may worsen gastrointestinal irritation. (label Alendronat, Interaksi obat)

  • AliskirenantihipertensiModerat

    …part on the activity of the RAAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or patients receiving ARB, ACEI or nonsteroidal anti-inflammatory drug (NSAID), including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors), therapy may be at particular risk for developing acute renal failure… (label Aliskiren, Peringatan dan perhatian)

  • AlkoholAlkoholModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • Alogliptinpenghambat DPP-4Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Alogliptin dan metforminpenghambat DPP-4Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Alprostadilanalog prostaglandinModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Salsalat, Peringatan)

  • Amiloriddiuretik hemat kaliumModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Amlodipin dan benazeprilpenghambat kanal kalsium dihidropiridinModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Amlodipin dan olmesartanpenghambat kanal kalsium dihidropiridinModerat

    • Increased exposure of amlodipine when coadministered with CYP3A inhibitors Olmesartan medoxomil ( 7.2 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS) may lead to increased risk of renal impairment and loss of antihypertensive effect. (label Amlodipin dan olmesartan, Interaksi obat)

  • Amlodipin dan valsartanpenghambat kanal kalsium dihidropiridinModerat

    Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) : In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including valsartan, may… (label Amlodipin dan valsartan, Interaksi obat)

  • Amoksisilinantibiotik penisilinModerat

    Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. [When Salsalate tablets, USP are administered with aspirin, its protein binding is reduced, although the clearance of free Salsalate tablets,… (label Salsalat, Interaksi obat)

  • Amoksisilin dan klavulanatantibiotik penisilinModerat

    Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. [When Salsalate tablets, USP are administered with aspirin, its protein binding is reduced, although the clearance of free Salsalate tablets,… (label Salsalat, Interaksi obat)

  • Ampisilinantibiotik penisilinModerat

    Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. [When Salsalate tablets, USP are administered with aspirin, its protein binding is reduced, although the clearance of free Salsalate tablets,… (label Salsalat, Interaksi obat)

  • Ampisilin dan sulbaktamantibiotik penisilinModerat

    Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. [When Salsalate tablets, USP are administered with aspirin, its protein binding is reduced, although the clearance of free Salsalate tablets,… (label Salsalat, Interaksi obat)

  • Anagrelidobat yang memperpanjang interval QTModerat

    Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (label Anagrelid, Peringatan dan perhatian)

  • ArgatrobanantikoagulanModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • Asam etakrinatdiuretik loopModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Asam zoledronatbisfosfonatModerat

    Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (label Asam zoledronat, Interaksi obat)

  • Asetazolamidpenghambat karbonat anhidraseModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Atenolol dan klortalidonpenyekat betaModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Azelastin dan flutikasonantihistaminModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • Azilsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Non-steroidal Anti-Inflammatory Agents, including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan,… (label Azilsartan, Interaksi obat)

  • BalsalazidsalisilatModerat

    ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO SALSALATE AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. (label Salsalat, Interaksi obat)

  • BeklometasonkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • Beksagliflozinpenghambat SGLT2Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Benazeprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Benazepril dan hidroklorotiazidpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Benzilpenisilin (penisilin G)antibiotik penisilinModerat

    Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. [When Salsalate tablets, USP are administered with aspirin, its protein binding is reduced, although the clearance of free Salsalate tablets,… (label Salsalat, Interaksi obat)

  • BetametasonkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • Bimatoprostanalog prostaglandinModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Salsalat, Peringatan)

  • Bismut subsalisilatsalisilatModerat

    ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO SALSALATE AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. (label Salsalat, Interaksi obat)

  • Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • BivalirudinantikoagulanModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • Brinzolamidpenghambat karbonat anhidraseModerat

    • Rare instances of acid-base alterations have occurred with high-dose salicylate therapy. (label Brinzolamid, Interaksi obat)

  • Bromokriptinagonis dopaminModerat

    Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (label Bromokriptin, Interaksi obat)

  • BudesonidkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • Budesonid dan formoterolkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • Bumetaniddiuretik loopModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Dapagliflozinpenghambat SGLT2Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Dapagliflozin dan metforminpenghambat SGLT2Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Deferasirokssuplemen zat besiModerat

    The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (label Deferasiroks, Peringatan dan perhatian)

  • DeflazakortkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • DeksametasonkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • …Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (label Desmopresin, Interaksi obat)

  • Desogestrel dan etinilestradiolkontrasepsi oralModerat

    COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. (label Desogestrel dan etinilestradiol, Interaksi obat)

  • DesonidkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • DesvenlafaksinSNRIModerat

    • Increased Risk of Bleeding: Concomitant use of aspirin, NSAIDs, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.4 ). (label Desvenlafaksin, Peringatan dan perhatian)

  • Dikloksasilinantibiotik penisilinModerat

    Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. [When Salsalate tablets, USP are administered with aspirin, its protein binding is reduced, although the clearance of free Salsalate tablets,… (label Salsalat, Interaksi obat)

  • Diklorfenamidpenghambat karbonat anhidraseModerat

    Concomitant Use of Aspirin or Other Salicylates Carbonic anhydrase inhibitors, including KEVEYIS, can cause metabolic acidosis [see Warnings and Precautions (5.4) ] , which can increase the risk of salicylate toxicity. (label Diklorfenamid, Peringatan dan perhatian)

  • Dinoprostonanalog prostaglandinModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Salsalat, Peringatan)

  • Donepezilpenghambat kolinesteraseModerat

    Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (label Donepezil, Peringatan dan perhatian)

  • Dorzolamidpenghambat karbonat anhidraseModerat

    High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (label Dorzolamid, Interaksi obat)

  • Dorzolamid dan timololpenghambat karbonat anhidraseModerat

    High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (label Dorzolamid dan timolol, Interaksi obat)

  • Drospirenon dan etinilestradiolkontrasepsi oralModerat

    Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (label Drospirenon dan etinilestradiol, Peringatan dan perhatian)

  • Dulaglutidagonis reseptor GLP-1Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • DuloksetinSNRIModerat

    Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anti-coagulants may add to this risk. (label Duloksetin, Peringatan dan perhatian)

  • Eksenatidagonis reseptor GLP-1Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (label Elvitegravir, kobisistat, emtrisitabin, dan tenofovir, Peringatan dan perhatian)

  • Empagliflozinpenghambat SGLT2Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Empagliflozin dan metforminpenghambat SGLT2Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Emtrisitabin dan tenofovirantiretroviralModerat

    Individuals taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (label Emtrisitabin dan tenofovir, Peringatan dan perhatian)

  • Enalaprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Enalapril dan hidroklorotiazidpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Enalaprilatpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Eplerenonantagonis aldosteronModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Epoprostenolanalog prostaglandinModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Salsalat, Peringatan)

  • EptifibatidantiplateletModerat

    Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, nonsteroidal anti-inflammatory drugs, and P2Y 12 inhibitors). (label Eptifibatid, Peringatan dan perhatian)

  • ErlotinibModerat

    Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (label Erlotinib, Peringatan dan perhatian)

  • EsitalopramSSRIModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • CHCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid and temazepam. (label Etonogestrel dan etinilestradiol, Interaksi obat)

  • Febuksostatpenghambat xantin oksidaseModerat

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (label Febuksostat, Peringatan dan perhatian)

  • FenitoinantikonvulsanModerat

    Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. [When Salsalate tablets, USP are administered with aspirin, its protein binding is reduced, although the clearance of free Salsalate tablets,… (label Salsalat, Interaksi obat)

  • Fenoksimetilpenisilin (penisilin V)antibiotik penisilinModerat

    Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. [When Salsalate tablets, USP are administered with aspirin, its protein binding is reduced, although the clearance of free Salsalate tablets,… (label Salsalat, Interaksi obat)

  • FludrokortisonkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • Flukonazolantijamur azolModerat

    Non-steroidal anti-inflammatory drugs The C max and AUC of flurbiprofen were increased by 23% and 81%, respectively, when coadministered with fluconazole compared to administration of flurbiprofen alone. (label Flukonazol, Interaksi obat)

  • FlunisolidkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • FluoksetinSSRIModerat

    Use with NSAIDs, aspirin, warfarin, or other drugs that affect coagulation may potentiate the risk of gastrointestinal or other bleeding ( 5.7 ) (label Fluoksetin, Peringatan dan perhatian)

  • FluosinonidkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • FlutikasonkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • Flutikason dan salmeterolkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • FluvoksaminSSRIModerat

    Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (label Fluvoksamin, Peringatan dan perhatian)

  • FosfenitoinantikonvulsanModerat

    …sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antineoplastic agents usually in combination Bleomycin, carboplatin, cisplatin,… (label Fosfenitoin, Interaksi obat)

  • Fosinoprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Fosinopril dan hidroklorotiazidpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Furosemiddiuretik loopModerat

    Furosemide Clinical studies, as well as post marketing observations, have shown that Salsalate tablets, USP can reduce the natriuretic effect-of furosemide and thiazides in some patients. (label Salsalat, Interaksi obat)

  • Galantaminpenghambat kolinesteraseModerat

    Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

  • GlibenklamidsulfonilureaModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Glibenklamid dan metforminsulfonilureaModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • GlimepiridsulfonilureaModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • GlipizidsulfonilureaModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Glipizid dan metforminsulfonilureaModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • GriseofulvinantijamurModerat

    Serum salicylate concentrations may be decreased when griseofulvin is given concomitantly with salicylates. (label Griseofulvin, Interaksi obat)

  • HalobetasolkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • HeparinantikoagulanModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • • Large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect ( 7.4 ) (label Hialuronidase, Interaksi obat)

  • Hidroklorotiaziddiuretik tiazidModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • HidrokortisonkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • IbandronatbisfosfonatModerat

    Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. (label Ibandronat, Interaksi obat)

  • Indapamiddiuretik tiazidModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Insulin aspartinsulinModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Insulin degludekinsulinModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Insulin detemirinsulinModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Insulin glargininsulinModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Insulin lisproinsulinModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Irbesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and COX-2 inhibitors: Increased risk of renal impairment. (label Irbesartan, Interaksi obat)

  • Irbesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Itrakonazolantijamur azolModerat

    Nonsteroidal Anti-Inflammatory Drugs Meloxicam Concomitant drug dose increase may be necessary. (label Itrakonazol, Interaksi obat)

  • Kalium kloridasuplemen kaliumModerat

    Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

  • Kalium sitratsuplemen kaliumModerat

    Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) (label Kalium sitrat, Interaksi obat)

  • Kanagliflozinpenghambat SGLT2Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Kandesartanpenghambat reseptor angiotensin II (ARB)Moderat

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (label Kandesartan, Interaksi obat)

  • Kandesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Kaptoprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Karboprostanalog prostaglandinModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Salsalat, Peringatan)

  • KlobetasolkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • KlopidogrelantiplateletModerat

    Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

  • Klorotiaziddiuretik tiazidModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Klortalidondiuretik tiazidModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Kuinaprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Kuinapril dan hidroklorotiazidpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Latanoprostanalog prostaglandinModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Salsalat, Peringatan)

  • LevofloksasinfluorokuinolonModerat

    Non-Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including Levofloxacin in 5% Dextrose Injection, may increase the risk of CNS stimulation and convulsive seizures [see Warnings and Precautions (5.4) ]. (label Levofloksasin, Interaksi obat)

  • LevomilnasipranSNRIModerat

    Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (label Levomilnasipran, Peringatan dan perhatian)

  • Levonorgestrel dan etinilestradiolkontrasepsi oralModerat

    Other Drugs Clinical effect Concomitant use of CHCs may decrease systemic exposure of acetaminophen, morphine, salicylic acid, and temazepam. (label Levonorgestrel dan etinilestradiol, Interaksi obat)

  • Levotiroksinhormon tiroidModerat

    An initial increase in serum FT 4 is followed by return of FT 4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T 4 levels may decrease by as much as 30%. (label Levotiroksin, Interaksi obat)

  • Linagliptinpenghambat DPP-4Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Linagliptin dan metforminpenghambat DPP-4Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Liotironinhormon tiroidModerat

    An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%. (label Liotironin, Interaksi obat)

  • Liraglutidagonis reseptor GLP-1Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Lisinoprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Lisinopril dan hidroklorotiazidpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Litiumobat serotonergikModerat

    Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. (label Salsalat, Interaksi obat)

  • Losartanpenghambat reseptor angiotensin II (ARB)Moderat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • Losartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Memantin dan donepezilpenghambat kolinesteraseModerat

    Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (label Memantin dan donepezil, Peringatan dan perhatian)

  • ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO SALSALATE AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. (label Salsalat, Interaksi obat)

  • MesalazinsalisilatModerat

    ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO SALSALATE AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. (label Salsalat, Interaksi obat)

  • MetforminbiguanidModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • MetilprednisolonkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • Metolazondiuretik tiazidModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Mifepristonpenghambat CYP3A4Moderat

    When given concomitantly with mifepristone, drugs that are substrates of CYP2C8/2C9 (including non-steroidal anti-inflammatory drugs, warfarin, and repaglinide) should be used at the smallest recommended doses, and patients should be closely monitored for adverse effects. [See Clinical Pharmacology ( 12.3 )] 7.5 Drugs Metabolized by CYP2B6 Mifepristone is an… (label Mifepriston, Interaksi obat)

  • MiglitolantidiabetesModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • MilnasipranSNRIModerat

    Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (label Milnasipran, Peringatan dan perhatian)

  • Moeksiprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • MoksifloksasinfluorokuinolonModerat

    Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Although not observed with moxifloxacin in preclinical and clinical trials, the concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions [see Warnings and Precautions ( 5.4 ), and Patient Counseling Information ( 17 )]. (label Moksifloksasin, Interaksi obat)

  • MometasonkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • Nafsilinantibiotik penisilinModerat

    Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. [When Salsalate tablets, USP are administered with aspirin, its protein binding is reduced, although the clearance of free Salsalate tablets,… (label Salsalat, Interaksi obat)

  • NateglinidmeglitinidModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (label Natrium fenilasetat dan natrium benzoat, Peringatan dan perhatian)

  • NintedanibModerat

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (label Nintedanib, Peringatan dan perhatian)

  • Nizatidinpenghambat H2Moderat

    In patients given very high doses (3,900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently. (label Nizatidin, Interaksi obat)

  • CHCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, and temazepam. (label Norelgestromin dan etinilestradiol, Interaksi obat)

  • Norgestimat dan etinilestradiolkontrasepsi oralModerat

    COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. (label Norgestimat dan etinilestradiol, Interaksi obat)

  • Norgestrel dan etinilestradiolkontrasepsi oralModerat

    COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. (label Norgestrel dan etinilestradiol, Interaksi obat)

  • OfloksasinfluorokuinolonModerat

    Non Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a quinolone, including ofloxacin, may increase the risk of CNS stimulation and convulsive seizures (see WARNINGS and PRECAUTIONS , General ). (label Ofloksasin, Interaksi obat)

  • Oksasilinantibiotik penisilinModerat

    Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. [When Salsalate tablets, USP are administered with aspirin, its protein binding is reduced, although the clearance of free Salsalate tablets,… (label Salsalat, Interaksi obat)

  • Olanzapin dan fluoksetinantipsikotikModerat

    Use with NSAIDs, aspirin, warfarin, or other drugs that affect coagulation may potentiate the risk of gastrointestinal or other bleeding ( 5.16 ) (label Olanzapin dan fluoksetin, Peringatan dan perhatian)

  • Olmesartanpenghambat reseptor angiotensin II (ARB)Moderat

    NSAID use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7.2 ). (label Olmesartan, Interaksi obat)

  • Olmesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Olopatadin dan mometasonantihistaminModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • ParoksetinSSRIModerat

    Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (label Paroksetin, Peringatan dan perhatian)

  • PentoksifilinmetilxantinModerat

    DRUG INTERACTIONS Bleeding has been reported in patients treated with pentoxifylline extended-release tablets with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. (label Pentoksifilin, Interaksi obat)

  • Perindoprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • PioglitazontiazolidindionModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Pioglitazon dan glimepiridtiazolidindionModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Pioglitazon dan metformintiazolidindionModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Piperasilin dan tazobaktamantibiotik penisilinModerat

    Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. [When Salsalate tablets, USP are administered with aspirin, its protein binding is reduced, although the clearance of free Salsalate tablets,… (label Salsalat, Interaksi obat)

  • PrednisolonkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • PrednisonkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • Ramiprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • RepaglinidmeglitinidModerat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Rivastigminpenghambat kolinesteraseModerat

    Monitor patients using rivastigmine tartrate for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (label Rivastigmin, Peringatan dan perhatian)

  • Saksagliptinpenghambat DPP-4Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Saksagliptin dan metforminpenghambat DPP-4Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Sakubitril dan valsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): May lead to increased risk of renal impairment. (label Sakubitril dan valsartan, Interaksi obat)

  • SefotaksimsefalosporinModerat

    Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (label Sefotaksim, Interaksi obat)

  • Semaglutidagonis reseptor GLP-1Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • SertralinSSRIModerat

    Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (label Sertralin, Peringatan dan perhatian)

  • SiklesonidkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • SiklosporinimunosupresanModerat

    In addition, concomitant use of NSAIDs with cyclosporine, particularly in the setting of dehydration, may potentiate renal dysfunction. (label Siklosporin, Interaksi obat)

  • SiprofloksasinfluorokuinolonModerat

    NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. (label Siprofloksasin, Interaksi obat)

  • Sitagliptinpenghambat DPP-4Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • Sitagliptin dan metforminpenghambat DPP-4Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • SitalopramSSRIModerat

    Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk. (label Sitalopram, Peringatan dan perhatian)

  • Spironolaktonantagonis aldosteronModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Spironolakton dan hidroklorotiazidantagonis aldosteronModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • SulfadiazinsulfonamidaModerat

    Conversely, agents such as indomethacin, probenecid and salicylates may displace sulfonamides from plasma albumin and increase the concentrations of free drug in plasma. (label Sulfadiazin, Interaksi obat)

  • SulfasalazinsulfonamidaModerat

    ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO SALSALATE AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. (label Salsalat, Interaksi obat)

  • Telmisartanpenghambat reseptor angiotensin II (ARB)Moderat

    Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including telmisartan, may… (label Telmisartan, Interaksi obat)

  • Telmisartan dan amlodipinpenghambat reseptor angiotensin II (ARB)Moderat

    NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (label Telmisartan dan amlodipin, Interaksi obat)

  • Telmisartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Tembakau dan merokokTembakau dan ganjaModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • Tirzepatidagonis reseptor GLP-1Moderat

    Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

  • TofasitinibimunosupresanModerat

    Promptly evaluate patients treated with XELJANZ/XELJANZ XR who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs) and who present with new onset abdominal symptoms for early identification of gastrointestinal perforation [see Adverse Reactions (6.1) ] . (label Tofasitinib, Peringatan dan perhatian)

  • Torasemiddiuretik loopModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Trandolaprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • TrazodonantidepresanModerat

    Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (label Trazodon, Peringatan dan perhatian)

  • Treprostinilanalog prostaglandinModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Salsalat, Peringatan)

  • TriamsinolonkortikosteroidModerat

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (label Salsalat, Peringatan)

  • Triamterendiuretik hemat kaliumModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • Triamteren dan hidroklorotiaziddiuretik hemat kaliumModerat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • UpadasitinibimunosupresanModerat

    Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (label Upadasitinib, Peringatan dan perhatian)

  • Valsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Non-Steroidal Anti-Inflammatory Drug (NSAID) use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7.2 ) (label Valsartan, Interaksi obat)

  • Valsartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (label Salsalat, Peringatan)

  • VenlafaksinSNRIModerat

    Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

  • VilazodonSSRIModerat

    Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (label Vilazodon, Peringatan dan perhatian)

  • Vorikonazolantijamur azolModerat

    NSAIDs Non-Steroidal Anti-Inflammatory Drug including. ibuprofen and diclofenac (CYP2C9 Inhibition) Increased Frequent monitoring for adverse reactions and toxicity related to NSAIDs. (label Vorikonazol, Interaksi obat)

  • VortioksetinantidepresanModerat

    • Increased Risk of Bleeding : Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, or other drugs that affect coagulation may increase risk ( 5.3 ). (label Vortioksetin, Peringatan dan perhatian)

  • WarfarinantikoagulanModerat

    Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. [When Salsalate tablets, USP are administered with aspirin, its protein binding is reduced, although the clearance of free Salsalate tablets,… (label Salsalat, Interaksi obat)

Penyebutan minor (40)

  • Amlodipinpenghambat kanal kalsium dihidropiridinMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Amlodipin dan atorvastatinpenghambat kanal kalsium dihidropiridinMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Asebutololpenyekat betaMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Atenololpenyekat betaMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Betaksololpenyekat betaMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Bisoprololpenyekat betaMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Doksazosinpenyekat alfaMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin, salicylic acid, phenylbutazone, and diazepam. (label Entakapon, Perhatian)

  • Felodipinpenghambat kanal kalsium dihidropiridinMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Fenoksibenzaminpenyekat alfaMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Finasteridpenghambat 5-alfa reduktaseMinor

    …angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions. (label Finasterid, Interaksi obat)

  • Guanfasinagonis alfa-adrenergikMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • HidralazinvasodilatorMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • InfliksimabimunosupresanMinor

    In RA, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents (NSAIDs), folic acid, corticosteroids and/or narcotics. (label Infliksimab, Interaksi obat)

  • DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Isradipinpenghambat kanal kalsium dihidropiridinMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Karvedilolpenyekat betaMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Klonidinagonis alfa-adrenergikMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Labetalolpenyekat betaMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (label Lenalidomid, Peringatan dan perhatian)

  • Lofeksidinagonis alfa-adrenergikMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • MekamilaminantihipertensiMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • MetildopaantihipertensiMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Metoprololpenyekat betaMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • MinoksidilvasodilatorMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Nadololpenyekat betaMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Nebivololpenyekat betaMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Nifedipinpenghambat kanal kalsium dihidropiridinMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Nikardipinpenghambat kanal kalsium dihidropiridinMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Nisoldipinpenghambat kanal kalsium dihidropiridinMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • NitroprusidvasodilatorMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Pindololpenyekat betaMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Prazosinpenyekat alfaMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Propranololpenyekat betaMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • RisedronatbisfosfonatMinor

    Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (label Risedronat, Interaksi obat)

  • Terazosinpenyekat alfaMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • Tizanidinpelemas ototMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

  • TosilizumabimunosupresanMinor

    Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (label Tosilizumab, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumMinor

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (label Salsalat, Interaksi obat)

Periksa Salsalat terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.